^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib

Excerpt:
Here we describe a case of a 63-year-old man...Then the patient received a nine-cycle combination treatment of XELOX and bevacizumab and showed progressive disease (PD)….Paraffin sections of postoperative colorectal tissue were subjected to next-generation sequencing, and epidermal growth factor receptor (EGFR) amplification and rare EGFR-SEPT14 fusion were identified.
Secondary therapy:
CAPOX
DOI:
10.1634/theoncologist.2019-0405